Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now
We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are ...
S&P 500 Gains and Losses Today: Index Tumbles as Economic Concerns Intensify
The S&P 500 dropped 2.7% on Monday, March 10, as U.S. tariffs and government job cuts heightened economic uncertainty and ...
Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study
Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...
AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies
Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.
Healio18h
Itch, urticaria activity improve with dupilumab after refractory antihistamine treatment
Patients with chronic spontaneous urticaria that was not controlled with H1 antihistamines experienced improvements in itch and urticaria activity with dupilumab, according to a poster presented here.
The Pharma Letter19h
Dupixent shows promise in treating bullous pemphigoid
Positive results from the ADEPT Phase II/III study indicate that Dupixent (dupilumab) may be effective in treating ...
PharmiWeb21h
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...
Fierce Biotech21h
Amgen ignites Rocket program with phase 3 wins for $400M eczema prospect
Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...